The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JSPR | -91.78% | N/A | N/A | -98% |
| S&P | +18.54% | +92.9% | +14.04% | +107% |
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.26M | 13.7% |
| Market Cap | $83.37M | -75.7% |
| Market Cap / Employee | $1.94M | 0.0% |
| Employees | 43 | 0.0% |
| Net Income | -$26.72M | -83.2% |
| EBITDA | -$26.82M | -70.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $39.51M | -63.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.20M | -84.4% |
| Short Term Debt | $1.95M | 89.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -113.37% | -60.9% |
| Return On Invested Capital | -128.16% | 3.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15.46M | -30.6% |
| Operating Free Cash Flow | -$15.45M | -32.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.83 | 3.83 | 1.05 | 1.97 | -34.74% |
| Price to Tangible Book Value | 2.83 | 3.83 | 1.05 | 1.97 | -34.74% |
| Enterprise Value to EBITDA | -9.91 | -10.03 | -0.85 | -1.78 | -88.14% |
| Return on Equity | -71.5% | -101.7% | -101.3% | -146.9% | 147.60% |
| Total Debt | $2.07M | $1.81M | $2.59M | $2.16M | -6.95% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
